Are Patients With MASH- or Alcohol-Associated Cirrhosis More Likely to Develop Hepatic Hydrothorax? A National Transplant Database Analysis

Authors

Sarpong Boateng, Internal Medicine, Bridgeport Hospital/Yale New Haven Health, Bridgeport, USA.

Document Type

Conference Proceeding

Abstract

Hepatic hydrothorax (HH) is a complication of end-stage liver disease involving the accumulation of pleural fluid in patients with cirrhosis, in the absence of other cardiopulmonary disease. HH occurs in 10% of patients with decompensated cirrhosis, conferring a 5-fold increased risk of mortality.¹ Alcohol-associated liver disease (ALD) and metabolic dysfunction associated steatohepatitis (MASH), which accounts for 80% of liver cirrhosis in the US are known risk factors for HH. ²

REFERENCES

1. Asrani, Sumeet K., et al. "Burden of liver diseases in the world." Journal of hepatology 70.1 (2019): 151-171.

2. Banini, Bubu A., et al. "Multidisciplinary management of hepatic hydrothorax in 2020: an evidence‐based review and guidance." Hepatology 72.5 (2020): 1851-1863.

Publication Date

Fall 2024

Recommended Citation

Boateng, Sarpong, "Are Patients With MASH- or Alcohol-Associated Cirrhosis More Likely to Develop Hepatic Hydrothorax? A National Transplant Database Analysis" (2024). Posters. 36.
https://scholar.bridgeporthospital.org/poster_presentations/36